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ABSTRACT
IMPROVED ONCOLYTIC VIROTHERAPY BY INCREASING VIRUS SPREAD WITHIN TUMORS
Stephen Wechman
December 17, 2014

Oncolytic adenoviruses (Ads) have great therapeutic potential for lung cancer.
Cancer selective E1b-deleted Ads are safe, however their efficacy remains
limited clinically. To improve E1b-deleted Ads, Adhz60 was selected for greater
anti-cancer efficacy by a process called bioselection, producing AdUV. AdUV
preferentially lysed A549 and H1299 lung cancer cells more effectively than both
the cancer selective Adhz60 and non-selective Ad5. AdUV induced greater LC3II expression, relative to LC3-I, indicating that AdUV (30.9-fold) induced
autophagy more effectively than Ad5 (12.2-fold) and Adhz60 (7.8-fold) in A549
cells. Mice treated with AdUV had significantly smaller tumors (p-value < 0.001)
and prolonged survival (p-value = 0.0005) than mice treated with the negative
control AdGFP. These results suggest that AdUV efficiently lyses lung cancer
cells in vitro and in vivo.
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CHAPTER I
INTRODUCTION
The leading cause of death from cancer is lung cancer. The number of
lung cancer deaths (159,260) in 2014 was comparable to the number of deaths
(159,810) from the next four leading cancers combined: colon, breast, pancreatic,
and prostate (American Cancer Society). The Surveillance Epidemiology and
End Results (SEER) statistics indicate that the five-year survival rate of lung
cancer patients improved from 11.4% in 1975 to 17.5% in 2006. Lung cancer will
continue to be a leading cause of death unless more effective treatments are
developed.
Surgery is the best treatment option for early stage lung cancer. Lung
cancer is staged using the Tumor Nodes Metastasis (TNM) system. Using this
system, each patient is staged based upon the size of his/her primary tumor,
lymph node involvement, and the presence or absence of distant metastasis [1].
Stage I lung tumors are less than 3 cm while stage II lung tumors are less than 7
cm in size [1]. Neither stage I nor stage II lung tumors have invaded tissue
beyond their primary site, therefore lobe resection is feasible for most stage I and
stage II lung cancer patients [2]. When lung cancer is surgically resected, 85% of
stage I and 77% of stage II cancer patients survive at least two years after
treatment [3]. Surgically resected stage II lung cancer is also frequently treated
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with adjuvant platinum-based chemotherapeutics [4]. Therefore, surgery remains
the best treatment option for early stage lung cancer.
For lung cancer patients beyond stage II, the combination of surgery,
intravenous (IV) chemotherapy and radiation offer the best results clinically [5-7].
Stage III lung tumors are greater than 7 cm in size and have invaded one of the
surrounding lung tissues such as the chest wall, pleura, or main bronchus [1].
Stage IV lung tumors can be of any size, however distant metastasis must be
observed [1]. These distant metastases are frequently observed in the adrenal
glands, bone, the opposite lung, liver or brain [8, 9]. The majority (57%) of lung
cancer patients have distant metastases at the time of diagnosis. Therefore,
most lung cancer patients are ineligible for surgery. Cancer chemotherapy has
not significantly improved lung cancer patient survival despite the investigation of
several different chemotherapeutic combinations clinically [10-12]. To treat lung
cancer patients more effectively, novel cancer therapeutics and strategies are
necessary.
The use of cancer selective viruses or oncolytic virotherapy is an
emerging lung cancer treatment [13, 14]. Oncolytic adenovirus (Ad) therapy is
unique because Ads can spread within tumors following the initial infection of a
small number of cancer cells [13, 15]. Cancer selective Ads are generated by the
attenuation of viral genes such as by the deletion of E1b-19K and E1b-55K [1618]. ONYX-015 (dl1520) was the first cancer selective, E1b-55k deleted Ad
studied clinically [19-21]. Many clinical trials studying E1b-deleted Ads have
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recruited head and neck cancer patients as these tumors are accessible for
intratumoral injection (IT). E1b-deleted Ads such as dl1520 displayed favorable
characteristics during several preclinical and clinical studies [20-22]. A virus very
similar to dl1520, H101, was approved commercially in China for cancer therapy
in combination with the PF chemotherapy regimen (cisplatin and fluorouracil) by
the China Food and Drug Administration (CFDA) [23]. In a phase III trial, H101
treatment increased the tumor response rate in head and neck cancer patients
treated with the PF regimen from 39.6% to 78.8% [24].
Ads are especially promising for the treatment of lung cancer. Ads have
respiratory tropism, allowing them to very efficiently infect and therapeutically
spread throughout the lung [25]. As a proof of concept, E1b-deleted Ads were
shown to efficiently kill primary lung tumor cultures isolated at 0.1 multiplicity of
infection (MOI) in vitro [26]. In a phase II clinical trial, Nemunaitis et. al.
administered dl1520 intravenously (IV) at increasing doses to patients with
metastatic lung cancer [27]. Their research revealed that dl1520 could infect and
replicate within lung cancer patients tumors following IV injection. No serious
side-effects were observed following dl1520 treatment [27]. Furthermore, Ads
interact synergistically with cancer chemotherapy as shown in primary lung
cancer tissue in vitro and lung cancer xenograft models in vivo [22, 26, 28].
Cheng et. al. and Chen et. al. also reported synergistic interactions when E1bdeleted Ads were combined with rapamycin or indol-3-carbinol respectively in
vitro [28, 29]. These studies indicate that adenovirus therapy is safe and
cooperates with many cancer chemotherapeutics.
3

Multiple clinical trials have shown that Ads are safe and cancer selective,
however their efficacy must be improved [19, 21, 23, 30, 31]. Bioselection can
generate viruses with greater anti-cancer activity [32-34]. Bioselection typically
entails the infection of cancer cells with viruses treated with mutagenic agents
and reinoculated within cancer cell cultures. In this case, Adhz60 was treated
with UV-light prior to the infection of the Ad-resistant Soas-2 cancer cells to
select for more effective, cancer therapeutic Ads. Using bioselection, viruses with
enhanced anti-cancer efficacy can be isolated without requiring a complete
understanding of their virus-host interactions [32, 35]. By UV-irradiating Adhz60
and reinoculation in Soas-2 Ad-resistant cancer cells, AdUV was isolated (Fig. 1).
AdUV displayed greater anti-cancer efficacy than Adhz60 in all cancer cell lines
tested. AdUV also induced autophagy more effectively than both Adhz60 and
Ad5 in A549 cells. These results suggest that AdUV may be released from and
spread between cancer cells very efficiently. In addition, AdUV significantly
suppressed the growth of A549 xenograft tumors and prolonged the survival of
athymic nu/nu mice. These studies have demonstrated the great therapeutic
potential of AdUV as a lung cancer therapeutic.
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Figure 1. The bioselection process. Adhz60 was amplified in HEK293 cells
prior to each cycle of UV-irradiation. Irradiated viruses (UVirrad) then infected the
Ad replication-resistant Soas-2 cancer cells. Viruses were harvested once
cytopathic effects (CPE) were observed in Soas-2 cells. Viruses harvested from
Soas-2 cells were then amplified in HEK293 cells before subsequent cycles of
UV irradiation and bioselection. After 72 cycles of bioselection, AdUV was
isolated by plaque purification from a large plaque formed upon Soas-2 cells.
Adhz60 was treated with 639 J/m2 UV type-C irradiation. UV-light was produced
by a germicidal UV-lamp as described in the materials and methods.
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CHAPTER II
MATERIALS AND METHODS
Cell lines and culture conditions
HEK293 (ATCC no. CRL-1573) human embryonic kidney, MRC5 (ATCC
no. CCL171) normal lung fibroblast, A549 (ATCC no. CCL-185) human lung
carcinoma, H1299 (ATCC no. CRL-5803) metastatic human lung carcinoma of
the lymph node, H441 (ATCC no. HTB-174) lung papillary adenocarcinoma, and
MCF7 (ATCC no. HTB-22) human breast adenocarcinoma cells were all
purchased from the American Type Culture Collection (Rockville, MD). A549,
MCF7, MRC5 and HEK293 cells were maintained in Dulbecco’s Modified Eagle’s
medium (DMEM). H1299 and H441 cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium. All cell culture media were supplemented with
10% fetal bovine serum, L-glutamine, and penicillin/streptomycin (100 U/mL). All
cells were cultured and maintained in humidified 5% CO2 incubators at 37oC. All
cell culture reagents were obtained from VWR (VWR, Radnor, PA).
Adenoviral vectors
Wildtype adenovirus serotype 5 (Ad5, ATCC no. VR-5) was used as a
non-selective Ad control. Adhz60 has a deletion of the entire E1b gene and
promoter and was used as a cancer selective Ad control [36]. AdGFP is an Ad

6

vector with the entire E1 gene (E1a, and E1b) deleted which expresses green
fluorescent protein (GFP) driven by the CMV promoter. AdGFP does not
replicate nor induce cytopathetic effects (CPE) in infected cells [28]. AdUV was
generated by a process known as bioselection as illustrated in Figure 1. UV-light
was used to irradiate Adhz60 for 5 minutes, inactivating approximately 90% of
virus particles. UV-light was produced by a germicidal lamp, USEG30T3
(Sylvania, Danvers, MA), fitted with a 30 watt G30T8 UV-light bulb (Philips,
Amsterdam, Netherlands) which produces UV type-C irradiation [37]. UV
irradiation was measured with a model 25X UVX radiometer (Fisher Scientific,
Waltham, MA). Using these conditions, 213 μW/cm2 UV type-C was produced,
generating a total UV dose of 639 J/m2 after five minutes UV-irradiation (300 s).
Irradiated viruses then used to infect Soas-2 cancer cells. Soas-2 cells do not
support efficient Ad replication [38]. Ads were harvested from Soas-2 cells once
CPE was observed. Harvested Ads were then amplified in HEK293 cells prior to
subsequent UV-light irradiation. After 72 cycles of bioselection, viral clones were
isolated by the plaque purification of large plaques formed on Soas-2 cells. The
most active clone, AdUV, was used in this study. All Ad constructs are based on
the Ad5 (wildtype) backbone sequence.
Viral infection and titration
Virus titer was determined using the infectious unit method as described
previously [18, 39]. HEK293 cells were seeded overnight onto 96-well plates at a
density of 1x103 cells per well and infected with virus samples serially diluted

7

tenfold. The presence or absence of CPE in HEK293 cells was recorded after a
minimum of 7 days incubation at 37oC to calculate the virus titer or the number of
virus particles per milliliter.
To determine the virus release kinetics, A549 cells were seeded into 12well plates at a density of 1x105 cells per well. Each well was infected with one
MOI of Ad5, Adhz60 or AdUV. Samples were collected at 6, 24, 36, 48, and 72
hours post-infection. The cell culture media and cells were collected together.
Virus infected cells were separated from the culture media by centrifugation
using a micromax RF refrigerated microcentrifuge (Thermo Fisher Scientific,
Waltham, MA) equipped with an IEC 851 rotor. Cells were centrifuged at 2,000
RPM (350 RCF), at 4oC for five minutes. Media samples were then frozen at 80oC, while cell pellets were resuspended in 1 mL of PBS and subjected to three
freeze-thaw to release all virus particles into solution [28, 40]. Viral titers were
then compared between Ad treatment groups by the number of virus particles
inside (pellet) or outside (supernatant) of A549 cells.
Western blot analysis
A549 Cells were seeded at a density of 6x105 per 60 mm dish and treated
as indicated. Cells were collected and centrifuged at 1,500 RPM (453 RCF) at
4oC for five minutes in an eppendorf 15 amp 5810 R refrigerated centrifuged
equipped with a A-4-62 rotor (Eppendorf, Hamburg, Germany). The cell pellets
were then washed with phosphate buffered saline (PBS) to remove serum
contained within the cell culture media prior to cell lysis with Radio immuno
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precipitation assay (RIPA) buffer containing 50 mM Tris-HCl, 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, and 0.1% sodium docecyl sulfate (SDS) with
a protease inhibitor (PI) cocktail containing 4-(2-aminoethyl)-benzenesulfonyl
fluoride

(AEBSF),

pepstatin

A,

L-trans-epoxysuccinyl-leucylamido(4-

guanidino)butane (E-64), bestatin, leupeptin, and aprotinin (10 mL/10 6 cells;
Sigma, St. Louis, MO). Cell pellets were incubated on ice in PI containing RIPA
buffer for 30 minutes and homogenized every 10 minutes using a vortex-genie 2
to lyse cells (Scientific Industries, Bohemia, NY). Cell lysates were then
centrifuged at 14,500 RPM (196,000 RCF) at 4oC for 10 minutes to remove cell
debris from the lysate using a Micromax RF microcentrifuge equipped with an
IEC 851 rotor (Thermo Fisher Scientific, Waltham, MA). The cell pellets were
discarded while the supernatant was stored for further experimentation. The
protein concentration of all lysates was determined using the Pierce BCA protein
assay kit according to the manufacturer’s instructions (Thermo Fisher Scientific,
Walton, MA). Equal amounts of cellular protein were resolved by electrophoresis
through either 8% (E1A, hexon, penton, protein V, protein VI, protein VII) or 12%
(LC3-I and LC3-II) SDS-polyacrylamide gels prior to transfer to Hybond-PVDF
membranes activated with methanol (GE healthcare, Little Chalfont, UK) using a
semi-dry transfer apparatus (BIO-RAD, Hercules, CA). Membranes were then
blocked using 5% nonfat milk prepared in Tris-Buffered saline with Tween 20
(TBST) for one hour at room temperature. To detect protein expression,
membranes were incubated with the following primary antibodies: rabbit-antiadenovirus type 5 polyclonal antibody (1:10,000; abcam, Cambridge, England),
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rabbit-anti-human LC3 monoclonal antibody (1:3,000; Novus Biologicals, Littleton,
CO), rabbit-anti-human actin (1:2,000; Sigma, Saint Louis, MO) or mouse-antiadenovirus E1A antibody (1:1,000; BD Pharmagen, San Jose, CA) at 4oC on a
lab-line thermal rocker overnight (Thermo Fisher Scientific, Waltham, MA).
Primary antibody binding was detected by the incubation with the horse radish
peroxidase (HRP) linked anti-mouse immunoglobin (Ig) or anti-rabbit Ig speciesspecific whole antibodies diluted 1:5,000 for one hour at room temperature
(Amersham, Piscataway, NJ). All antibodies were diluted in TBST. Enhanced
chemiluminescence (ECL) reagents were used to detect HRP-linked secondary
antibody binding according to the manufacturer’s instructions (Amersham,
Piscataway, NJ). Light produced by the reaction of ECL and HRP was detected
by exposure of membranes to CL-XPosure film 8 x 10 inches (Thermo Fisher
Scientific, Waltham, MA) in an autoradiography cassette (Thermo Scientific,
Pittsburgh, PA). Exposed films were then developed using a SRX-101A medical
film processor according to the manufacturer instructions (Konica Minolta, Toyko,
Japan). Developed films were then scanned using a Hewlett-Packard 4070
Scanjet scanner (Hewlett-Packard, Palo Alto, CA).
Plaque formation assay
A549 cells were seeded into 6-well plates at a density of 6x105 per well.
Cells were infected with Ad5, Adhz60 and AdUV at 0.01 MOI for 6 hours. The cell
culture media were then removed and replaced with 5 mL of 1% nutrient agarose
per well. The nutrient agarose was prepared by adding 1 g agarose (Fisher
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Scientific, Waltham, MA) to 15 mL of double distilled water (ddH20). This solution
was then autoclaved in a Getinge model 533LS vacuum steam sterilizer on a LQ15 cycle (Getinge, Lindholmen, Sweden). The agarose was then briefly reheated
in a microwave on high for 30 to 45 seconds and mixed with 85 mL complete
DMEM, the nutrient agarose medium was then equilibrated to approximately
44oC prior to addition to cell monolayers. Images were taken six days postinfection with an EVOS FL microscope (Life technologies, Carlsbad, CA) at 4X
magnification. The pixel densities of ten representative plaques per Ad5, Adhz60
and AdUV treatment groups were measured with the area density tool using Gelpro analyzer 4.0 software according to the manufacturer’s tutorial (Media
cybernetics, Rockville, MD). The total number of pixels for each plaque was
converted to millimeters (mm) by dividing the number of pixels per plaque by the
number of pixels per one mm2. The pixel length of one mm (510 pixels) was
determined by the 1,000 micrometer (µm) scale bar to yield the pixels per one
mm2 of 260,100 pixels.
Quantification of band intensity
Band intensities were quantified by Gel-pro analyzer 4.0 software in
accordance with the manufacturer’s tutorial (Media Cybernetics, Bethesda, MD).
Densitometric values were expressed as the integrated optical density (IOD) for
each band. These data were reported as the ratio of LC3-II/LC3-I with each LC3-I
and LC3-II band normalized to their respective to actin bands [28]. Mock treated
cells were represented as one-fold LC3-II/LC3-I expression.
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Cytotoxicity assay
Cells were seeded at a density of 2x104 (H1299), 3x104 (A549), 4x104
(MCF-7) or 6x104 (H441) cells per well onto 24-well plates. Cytotoxicity was
assessed by crystal violet staining [41]. Suspended cells were removed by
aspiration and the remaining adherent cells were fixed with 3.7% formaldehyde
for 20 minutes at room temperature. Excess formaldehyde was washed away
with PBS and cells were stained using 1% crystal violet at room temperature for
30 minutes. Excess crystal violet was washed away with water. Plates were then
scanned using an HP Scanjet 4070 scanner (HP, Palo Alto, CA). The remaining
crystal violet was then solubilized with a 2% sodium dodecyl sulfate (SDS)
solution and the sample absorbances were measured at 590 nm using a Synergy
HT Multi-Mode Microplate Reader (Bio-Tek, Winooski, VT). The absorbance (OD)
values were then normalized to mock treated cells converting each sample OD
into percent (%) cell viability by the formula, cell viability % = (OD of treated cells
/ OD of Mock treated cells) x 100%.
Lung cancer xenograft study
Tumors were formed by the subcutaneous injection (SC) of 5x106 A549
lung cancer cells into the right flank of athymic nu/nu mice. Palpable tumors were
observed two weeks following SC injection. Once tumors reached 30 mm3, mice
were randomized and treated by intratumoral injection (IT) with 5x108 plaque
forming units (PFU) of either AdGFP or AdUV. Tumor volumes were calculated
based upon the following equation, V = (L×W2)/2, where L is length and W is the
12

width of the tumor [40]. Both Ad treatments were suspended in 50 µL prior to IT
injection. Mice were injected four times with 5x108 PFU of each treatment in three
day intervals for a total dose of 2x109 PFU. Eight mice were treated with AdGFP
and seven mice were treated with AdUV. All animals were handled humanely
and all experiments were conducted using an approved IACUC protocol.
DNA Sequencing
DNA sequencing was performed at the University of Louisville KBRIN
bioinformatics core facility using Ion PGM Sequencing 200 kit v2 and Ion PGM
system. One Ion 314 v2 Chip was used for loading the enriched Ion One Touch
200 ISP samples. Open source integrated genomics viewer (IGV) software was
downloaded to view DNA sequence results. Mutations were considered to be
present when the DNA was altered in greater than 95% of total reads for each
gene region. Reading frames were observed using the translation track feature of
IGV to determine if detected DNA mutations altered amino acid sequences.
Statistical analysis
All experiments were repeated at least three times. Quantification of
results was reported as means of three independent experiments plus or minus
(±) the standard deviation. The Pearson correlation coefficient (r) was used to
evaluate the accuracy of equations used to calculate sample protein
concentrations with the Pierce BCA protein assay kit. Statistical significance was
assessed using analysis of variance analysis (ANOVA) and the Wilcoxon rank-
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sum test. Multiple comparisons of ANOVA tests were corrected using
Bonferroni’s method. Multiple comparisons of Wilcoxon ranked-sum were
corrected by Dunn’s test. Adjusted p-values are reported for each of these
multiple comparisons. These statistical tests cannot report adjusted p-values
greater than 1.0 or less than 0.0001. All statistical tests were conducted using
GraphPad software (Microsoft, Redmond, WA). Detailed methods for the
analysis of each dataset are provided as follows.
Figures 3A-D were analyzed using two-way ANOVA to compare Adhz60
versus Ad5 and Adhz60 versus AdUV treatment groups. Multiple comparisons
were made between each virus dose or MOI. The EC50 of each virus which
lysed treated cancer cells (Ad5, Adhz60 and AdUV) was also determined. First,
values were expressed as the percent death rather than percent viability the virus
dose was logarithmically transformed by the equation (x = log(x)). These data
were then fit to their respective dose-response curves using log-agonist vs.
normalized response regression analysis in Figure 3E. Considering AdUV had an
EC50 of one MOI in A549 cells, a two-way ANOVA was used to observe if these
data, Figure 3A-D, were significantly different at one MOI between all treatment
groups and cell lines as tabulated in Figure 4F. Figures 4B and 5B were
determined to have unequal variance between treatments groups by the KruskalWallis test. Therefore, Figures 4B and 5B were analyzed using the Wilcoxon
rank-sum test. Multiple comparisons were made using Dunn’s test to determine if
AdUV versus Ad5 and AdUV versus Adhz60 treatment groups were significantly
different. Figure 8A was analyzed using two-way ANOVA to determine if tumor
14

growth following AdGFP and AdUV treatment was significantly different at each
time-point (days). Figure 8C was analyzed using the Kaplan-Meijer Log-rank sum
test to determine if the survival of mice following AdGFP and AdUV treatment
was significantly different. These statistical tests were performed using
GraphPad Prism software (Microsoft, Redmond, WA). Statistical significance was
set at p < 0.05.

15

CHAPTER III
RESULTS
AdUV strongly destroys cancer cells.
AdUV was isolated by exposing Adhz60 to UV irradiation followed by
selection in Ad-replication resistant Soas-2 cancer cells as illustrated in Figure 1.
This process is called bioselection. The virus used for these studies, AdUV, was
isolated from a large plaque formed on Soas-2 cells. The anti-cancer activity of
AdUV was compared to the cancer non-selective wildtype Ad serotype 5 Ad5, the
cancer selective E1b-deleted Ad Adhz60, and the E1a, E1b-deleted negative
control Ad AdGFP. Ad5 and Adhz60 represent the positive and negative controls
for MRC5 cell lysis respectively. H1299 human lung cancer and MRC5 normal
lung cells were infected with AdGFP, Ad5, Adhz60, and AdUV at the indicated
multiplicities of infection (MOI) for five days (Fig. 2A). AdUV induced greater
cytopathic effect (CPE) than Adhz60 and Ad5 in H1299 lung cancer cells (Fig.
2A). AdUV also killed MRC5 normal cells more effectively than Adhz60, however
less than Ad5 at 10 MOI (Fig. 2A). Therefore to test if AdUV was cancer selective,
MRC5 normal and H1299 lung cancer cells were treated at MOI 10 and observed
for CPE (Fig. 2B). Ad5 induced CPE non-selectively in both normal lung and lung
cancer cells, while Adhz60 only induced CPE in H1299 lung cancer cells as
expected. AdUV induced less CPE in MRC5 normal cells at 10 MOI than Ad5,
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however AdUV induced more CPE in H1299 lung cancer cells than both Ad5 and
Adhz60 (Fig. 2A, B).
To study the oncolytic effects of AdUV further, A549, H1299, and H411
lung cancer and MCF-7 breast cancer cells were treated with AdGFP, Ad5,
Adhz60 or AdUV at the indicated MOIs for five days. The E1b-deleted Ad Adhz60
was applied as a cancer selective control [36]. Therefore, Ad5 and AdUV were
compared to Adhz60 to determine if Ad5 or AdUV displayed greater anti-cancer
efficacy than Adhz60. Cell viability was determined via crystal violet staining and
normalized to mock (0 MOI) treated cells (Fig. 3). Ad5 very effectively induced
cancer cell death in all four cancer cell lines tested, whereas AdGFP did not alter
cell viability (Fig. 2A-D). AdUV killed A549 lung cancer cells more effectively than
both Adhz60 (p-value = 0.0002) and Ad5 (p-value = 0.005) at 0.3 MOI (Fig. 3A).
AdUV also killed H1299 lung cancer cells more effectively than Ad5 (p-value <
0.0001) and Adhz60 (p-value < 0.0001) at 0.3 MOI (Fig. 3B). Treatment with Ad5
at one MOI was more effective than Adhz60 in H411 lung (p-value < 0.0001) and
MCF-7 breast (p-value = 0.0009) cancer cells respectively. Ad5 and AdUV
treatments were not significantly different in H441 and MCF7 cells (Fig. 3C-D).
Adhz60 was significantly less effective than both Ad5 and AdUV in all cancer cell
lines (Fig. 3A-D).
The viability of AdUV treated A549 cells was lower than Ad5 and Adhz60
at all viral doses (MOI) tested. Therefore, studies investigated how AdUV killed
A549 cells more effectively than Ad5. The EC50 values of Ad5, Adhz60 and
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AdUV were determined for each cancer cell line (Fig. 3E). The EC50 of AdUV
treated A549 cells was one MOI (0.99; Fig. 3E). Therefore, p-values were
reported to determine if statistically significant differences were observed at one
MOI between all Ads and cancer cell lines (Fig. 3F). These experiments taken
together indicate that AdUV killed multiple cancer cell lines very efficiently with
minimal effects upon MRC5 normal cells in vitro.
AdUV displays greater viral release from cells.
AdUV was selected for the efficient lysis of and release from cancer cells
during bioselection. Therefore, the plaque assay was used to study AdUV spread
through A549 lung cancer cells. AdUV formed larger plaques than Ad5 (p-value =
0.0248) and Adhz60 (p-value = 0.0002) in A549 cells (Fig. 4B). Larger plaque
formation is indicative of more efficient cell lysis, release, and spread.
To study if the replication of AdUV was altered via bioselection, A549 cells
were infected with Ad5, Adhz60 and AdUV at one MOI or the EC50 of AdUV (Fig.
3A, E). A549 cells infected with AdUV displayed greater E1A expression than
Adhz60 treated cells at 24 hours post-infection (Fig. 5A). A similar pattern was
observed at 72 hours as AdUV infected cells had greater late protein expression
than Adhz60 treated cells. Ad gene expression was not detected in the mock
treatment group.
The concentration of Ad particles in the cell culture media was studied to
determine if AdUV was released more efficiently from A549 cells than Ad5 and
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Adhz60 at one MOI, 48 hours post-infection. Adhz60 titer was 0.4-fold and AdUV
titer was 0.7-fold relative to Ad5 within the cell fraction of infected A549 cells.
AdUV titer was 3.3-fold in the cell-free fraction which was significantly greater
than Adhz60 (p-value = 0.02) which was 0.1-fold relative to Ad5 (Fig. 5B). These
data indicate that AdUV was released from A549 cells more efficiently than
Adhz60 but not Ad5.
To study the release kinetics of AdUV across time, A549 cells were
infected with Ad5, Adhz60 or AdUV at one MOI. Virus samples were collected
from these infected cells at 6, 24, 48, and 72 hours post-infection. Ad5 and AdUV
virus production was similar inside of A549 cells while Adhz60 virus titer was
slightly attenuated (Fig. 5C, left). The titer of AdUV was greater in the cell culture
media than both Ad5 and Adhz60 (1.5x106 of Ad5, 1.5x105 of Adhz60, and 5x106
of AdUV virus particles per ml at 48 hours) (Fig. 5C, right). AdUV was initially
released from A549 cells at 36 hours post-infection (Fig. 5C, right). After 36
hours AdUV virus release plateaued (Fig. 5C, right). Therefore, increased AdUV
release from A549 cells may contribute to the formation of larger plaques.
AdUV induces autophagy.
Autophagy was investigated to determine if increased autophagy induction
could explain the enhanced release and oncolysis phenotypes of AdUV.
Autophagy involves the lysosomal recycling of cytoplasmic organelles and long
lived proteins [48]. It has been reported that autophagy enhances Ad replication
perhaps by increasing cellular energy and nutrition for the assembly for virus
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particles [42]. During autophagy, LC3-I is produced by the cleavage of pro-LC3
by the cysteine protease Atg4 into LC3-I [43, 44]. LC3-I matures into LC3-II by
ATG3, ATG5, ATG7, and the ATG12-5 complex mediated conjugation of
phosphatidylethanolamine (PE) to the LC3-I glycine amino acid [45]. Therefore,
the LC3-II/LC3-I expression ratio was used to estimate autophagy induction and
autophagosome abundance [45, 46]. While Ads are known to induce autophagy,
it was necessary to confirm if AdUV induced LC3-II expression (Fig. 6A). AdUV
treatment increased the LC3-II/LC3-I expression ratio by 2.0, 7.0, 9.1, and 13.6
fold in A549 cells infected at 0.1, 0.3, 1, and 3 MOIs respectively (Fig. 6A). Thus,
LC3-II/LC3-I cleavage increased in a dose dependent manner with AdUV dose
(MOI). Then, one MOI was selected to observe if autophagy induction varied
between AdGFP, Ad5, Adhz60 and AdUV treatment groups five days postinfection. LC3-I conversion to LC3-II was detected in A549 cells treated with Ad5,
Adhz60 and AdUV but not in the negative controls, mock or AdGFP, treatment
groups (Fig. 6B). In this experiment, AdUV increased the LC3-II/LC3-I expression
ratio 30.9 fold, greater than both Ad5 (12.2 fold) and Adhz60 (7.8 fold; Fig. 6B).
A549 cells treated with one MOI of AdGFP, Ad5, Adhz60 or AdUV were
photographed to observe changes in A549 cell morphology (400 x) three days
post-infection. Cells treated with Ad5 and AdUV, but not AdGFP or Adhz60,
displayed

large

cytoplasmic

vesicles

indicating

autophagy

activation

morphologically at day three post-infection (Fig. 6C, arrowheads). These results
indicate that AdUV induced autophagy more effectively than both Ad5 and
Adhz60 in A549 cells.
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Ion-torrent DNA sequencing of AdUV.
AdUV DNA was sequenced to identify mutations induced during
bioselection [47]. Preliminary DNA sequencing revealed 31 mutations in the
AdUV genome after sequence alignment to wildtype reference sequences (Fig. 7)
[48]. Detailed analysis of mRNA open reading frames revealed that ten of these
DNA mutations have altered at least one of their encoded amino acid residues
(Fig. 7A). It is likely that some or all ten of these mutations are responsible for the
oncolytic phenotype of AdUV (Fig. 7B). The mutation to pIII resulted in a nonsense mutation, truncating twelve amino acids 559 – 571. Ad5 pIII has not been
studied, however studies of Ad serotype 2 (Ad2) indicate that pIII is highly
phosphorylated relative to other peptides in the Ad2 proteome [49]. Lind et. al.
predicted twelve phosphorylation sites were present in Ad2: one tyrosine, one
threonine and ten serines. The Ad2 phosphorylation site (503 – 519) on the
carboxy-terminus indicates that perhaps AdUV has lost a phosphorylation site at
its carboxy-terminus. Ad5 and Ad2 pIII peptides are each 571 amino acids long
and have 98.6% sequence identity. Another mutation to Iva2 at position 4952
changed the encoded glycine to an alanine. Iva2 is associated with virus
packaging, thus mutation of Iva2 could lead to a possible mechanism of
enhanced AdUV spread [50]. The mutation detected in pV at position 17387
changed a glycine to an arginine. Glycine is hydrophobic with a single hydrogen
atom as a side chain, however arginine has a six carbon nitrogenous side-chain
with a positive charge at physiological pH. The endogenous function of pV is to
bind Ad DNA to the capsid by interaction with p32 [51]. Therefore, the
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substitution of a neutral glycine for the positively charged (basic) arginine, may
allow pV to bind the negatively charged DNA sugar-phosphate backbone more
effectively. AdUV surprisingly is E1b-wildtype in addition to these mutations.
AdUV may have regained E1b via the homologous recombination with the E1
region of HEK293 during bioselection [52]. These mutations likely increased the
oncolytic efficacy of AdUV.
AdUV inhibits tumor growth in nude mice
DNA sequence analysis indicated that AdUV had regained the wildtype
E1b gene, therefore the lethality and therapeutic efficacy of AdUV was tested in
immunodeficient mice. The therapeutic effects of AdUV were evaluated using a
human A549 lung cancer tumor xenograft nu/nu athymic mouse model. Once
tumors reached 30 mm3 in size mice were randomized into the AdGFP and
AdUV treatment groups. Mice were injected intratumorally (IT) with 5×108 plaque
forming units (PFU) of AdGFP or AdUV prepared in 50 microliters (μL) of
phosphate-buffered saline (PBS). Four injections were administered to mice from
day six every three days until day fifteen. AdGFP was used as a negative control
for these studies. The length and width of each tumor was measured using
calipers every three days until day 125. Tumor volumes were calculated based
upon the following equation, V = (L×W 2)/2, where L is length and W is the width
of each tumor [40]. Mice were euthanized once tumor volumes exceeded 1,000
mm3. The tumor sizes between AdGFP and AdUV treatment groups reached
statistical significance at day thirty-three (p-value = 0.0363, Fig. 8A). AdUV
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treated tumors were significantly smaller (93.8%) than AdGFP treated tumors at
day 51 (p-value < 0.0001, Fig. 8A). Representative photographs of treated mice
indicated that AdUV strongly inhibited A549 tumor growth compared to AdGFP at
day fifty-one (Fig. 8B). All seven mice treated with AdUV survived until day 125
(p-value = 0.0005) while only two of eight total AdGFP treated mice survived (Fig.
8C). Thus, AdUV treatment significantly improved the survival of A549 tumorbearing mice compared to the AdGFP treatment group. Of the seven mice
treated with AdUV, two were tumor-free. The other five AdUV treated mice bore
tumors which no longer grew but remained palpable until day 151. It is possible
that AdUV was non-lethal in nude mice because human Ad replication is poor in
murine relative to human cells. Therefore, AdUV may not be cancer selective in
vivo. These results indicate that AdUV was safe and repressed A549 tumor
growth in athymic nude mice.
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CHAPTER IV
DISCUSSION
This study revealed the therapeutic potential of AdUV. AdUV was isolated
following the UV-irradiation of the E1b-deleted Ad Adhz60 and selected in the
Ad-resistant Soas-2 cancer cells during bioselection (Fig. 1) [36]. To my
knowledge, this is the first time that bioselection has been used upon a cancer
selective adenovirus (Ad). AdUV produced greater therapeutic effects than
Adhz60 in all cancer cell lines tested. Focusing upon A549 lung cancer cells, the
release of AdUV was greater than Adhz60 (p-value = 0.0204) but not Ad5 in vitro
(Fig. 5B). The increased killing effects of AdUV may be related to greater
autophagy induction in A549 cells (Fig. 6). Tumors treated with AdUV were
significantly smaller than tumors treated with the negative control AdGFP (pvalue < 0.0001; Fig. 8A). The overall survival of AdUV treated mice was
significantly greater than AdGFP treated mice (p-value = 0.0005; Fig. 8C). These
data indicate that AdUV is a promising lung cancer therapeutic agent with no
observed lethality to immunodeficient mice in vivo.
Most of these mutations were located in the Ad structural genes. The
absence of mutations to the early viral genes, such as E1 and E4, was surprising
as these genes have important roles of an array of virus-host interactions. By far,
cancer selective Ad research has focused primarily upon the modification of the
Ad early genes by the deletion of E1b genes, E1b-19K and E1b-55K, or the
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regulation of E1a gene expression using cancer-selective promoters [40, 53].
These results indicate that the late gene-encoded structural proteins may directly
influence oncolytic Ad release and oncolysis. To study these mutations further,
each mutation should be introduced into a well characterized Ad vector to
understand their impact upon Ad replication and therapy.
During

bioselection

AdUV

regained

E1b,

likely

via

homologous

recombination with the E1 sequences contained within HEK293 cells [52]. UV
irradiation has been shown to enhance Ad recombination in vitro [54]. These
results suggest that E1b may benefit Ad cancer therapy, even if E1b is not
essential for Ads to replicate and lyse cancer cells [38]. E1b-deleted Ads are safe,
however the mechanism of E1b-deleted Ad cancer selectivity has not been fully
characterized [23, 55]. Previously, Zhang et. al. showed that Ad E1B-55K can
induce the expression of the cell cycle-related genes, cyclin E and CDC25A [35].
The induction of cyclin E by E1B-55K was required for Ads to replicate in normal
cells, but not in cancer cells which frequently have deregulated cyclin E
expression [56]. The induction of cyclin E following Ad infection stimulates CDK2
phosphorylation at the S612 during Ad infection [56]. Therefore, cyclin E
deregulation in cancer cells may be an important target for the cancer selectivity
of E1b-55K deleted Ads [38]. This study indicates that while E1b-deleted Ads are
cancer selective they have limited efficacy, implicating the therapeutic potential of
E1b-wildtype Ads as demonstrated in the literature [57, 58]. Thus, innovative
strategies should be explored to develop more effective, cancer selective Ads.
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The lethality of the E1b-wildtype AdUV was observed upon A549-tumor
bearing in vivo. Mice were treated with the negative control AdGFP or the
experimental AdUV. AdUV treated tumors were significantly smaller than AdGFP
treated tumors at day fifty-one (p-value < 0.0001; Fig. 8A). Moreover, all seven
AdUV treated mice survived while only two of the eight AdGFP treated mice
survived until day 125 (p-value = 0.0005; Fig. 8B). No objective side-effects of
AdUV treatment were observed. It is possible that AdUV is safe in mice because
human Ad replication is poor in murine cells. These results indicate that AdUV
may be therapeutic and safe in immunodeficient murine models.
AdUV had greater efficacy than Adhz60 for the treatment of lung cancer
cells in vitro and was therapeutically effective in vivo. AdUV displayed greater
oncolytic efficacy in several cancer cell lines, producing larger plaques than Ad5
(p-value = 0.0248) and Adhz60 (p-value = 0.0002) in A549 cells (Fig. 4B). AdUV
was also a more effective autophagy inducer (30.9 fold) than both Ad5 (12.2 fold)
and Adhz60 (7.8 fold) in A549 cells (Fig. 6B). It appears that the acquisition of
E1b and/or mutations to the Ad late genes have increased the oncolytic potential
of AdUV. Additional studies may be required to understand how these mutations
affect Ad-mediated cancer cell lysis. These mutations should be recombined into
an E1b-deleted cancer selective Ad vector to determine they are beneficial when
incorporated into an E1b-deleted Ad background. Selective autophagy inducers
will be studied to identify new therapeutic combinations to maximize Ad cancer
therapy.
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FIGURES

Figure 2. The effect of AdUV upon normal lung and lung cancer cells. A)
H1299 lung cancer or MRC5 normal lung cell lines were treated with the
indicated MOIs of each adenovirus and stained with crystal violet after five days.
B) The Cytopathic effects (CPE) of cells treated at 10 MOI were photographed.
H1299 cells were photographed at day 3 post-infection. MRC5 cells were
photographed at day 5 post-infection.
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Figure 3. AdUV kills multiple cancer cell lines more effectively than Adhz60
in vitro. A549, H1299, H441 lung cancer cells and MCF-7 breast cancer cells
were treated with AdGFP, Ad5, Adhz60, or AdUV at the indicated MOIs. A-D)
Cytotoxicity was determined by crystal violet staining after five days infection.
Data was presented as the percent viability of treated cells relative to non-treated
cells ± the standard deviation of three independent experiments. E) EC50 values
were determined using GraphPad PRISM software. F) Two-way ANOVA with
multiple comparisons were conducted between all Ad treatments in each cancer
cell line at one MOI. All p-values were adjusted from two-way ANVOA analysis
adjusted for post-hoc testing for multiple comparisons corrected by Bonferroni’s
method. d.n.e. indicates the value does not exist, n.s. indicates a p-value > 0.05,
* Indicates a p-value < 0.05, † indicates a p-value < 0.01, ‡ indicates a p-value <
0.001.
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Figure 4. AdUV spread in A549 cell monolayers. A) Two representative
plaques of A549 cells treated with Ad5, Adhz60, and AdUV are shown. B) The
number of pixels contained within ten representative plaques was determined
and divided by the number of pixels per one mm2 to determine the size of each
plaque in millimeters (mm2). These data were plotted as the average ± the
standard deviation of ten plaques each (SD). Statistical significance was
assessed using the Wilcoxon rank-sum test. Adjusted p-values were reported for
multiple comparisons via Dunn’s test. n.s. indicates a p-value > 0.05, † indicates
a p-value < 0.01, ‡ indicates a p-value < 0.001.
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Figure 5. AdUV virus replication in A549 lung cancer cells. A) Ad protein
production was observed at different time-points in A549 cells treated with one
MOI of Ad5, Adhz60, or AdUV. B) Virus production inside and outside of A549
infected cells at one MOI after 48 hours infection was normalized to the average
Ad5 titer. Data is presented relative to Ad5 titer ± the standard deviation (SD) of
three independent replicates. C) A549 cells were infected at one MOI and viral
production was observed over time inside of and outside of infected A549 cells.
Significance was determined via the Wilcoxon rank-sum test. Adjusted p-values
were reported for multiple comparisons via Dunn’s test. * indicates p-value < 0.05.
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Figure 6. AdUV induces greater autophagy in A549 lung cancer cells. A)
A549 cells were infected with increasing MOIs of AdUV for five days. B) A549
cells were treated with one MOI of AdGFP, Ad5, Adhz60 and AdUV for five days.
A-B) LC3 expression was observed and the ratio of LC3-II to LC3-I was
quantified relative to actin using Gel-pro analyzer 4.0 software. C) Images of
A549 cells (400 x total magnification) treated with one MOI of AdGFP, Ad5,
Adhz60 and AdUV were shown three days post-infection. Arrowheads indicate
cytoplasmic vesicles in Ad treated A549 cells.
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Figure 7. DNA sequencing of AdUV. A) A genetic map showing the location of
mutations detected in AdUV relative to Ad5 wildtype sequences. The boxes
indicate the Ad exons. B) Table of AdUV DNA mutations, their location, and
changes to their amino acid sequences. The dark gray rows indicate alteration in
the amino acid biochemical properties of encoded amino acid sequences. The
dose of UV type-C (639 J/m2) irradiation was produced by a germicidal UV-lamp
and measured as described in the materials and methods.
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Figure 8. Treatment of xenograft tumors. Subcutaneous A549 tumor
xenografts were grown following the subcutaneous injection (SC) of 5x106 A549
cells in the right flank of nu/nu athymic mice. A) Tumors were injected
intratumorally (IT) with AdGFP or AdUV once they reached 30 mm3 in size. Mice
were treated by four IT injections from day six until day fifteen for a total dose of
2x109 PFU. B) Representative mice treated with AdGFP and AdUV were
photographed at day 51. Boxes indicate the magnified right flank of treated mice.
C) Animals were sacrificed once tumors were greater than 1,000 m3 in size.
Differences in tumor growth were assessed by two-way ANOVA with multiple
comparisons between the AdGFP and AdUV treatment groups per day. P-values
were adjusted via Bonferroni’s method. Differences in murine survival were
determined using the Kaplan-Meier log-rank sum test. * indicates p-value < 0.05,
† indicates p-value < 0.01, ‡ indicates p-value < 0.001.
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APPENDIX
List of Abbreviations
Ad

Adenovirus

Ad2

Adenovirus serotype 2

Ad5

Adenovirus serotype 5

Ads

Adenoviruses

AEBSF

4-(2-aminoethyl)-benzenesulfonyl fluoride

ANOVA

Analysis of Variance

Atg

Autophagy related

CFDA

China Food and Drug Administration

ddH20

Double Distilled Water

DMEM

Dulbecco’s Modified Eagle Medium

E1A

Early gene 1 A

E1B

Early gene 1 B

ECL

Enhanced Chemiluminescence

FBS

Fetal Bovine Serum

GFP

Green Fluorescent Protien

HRP

Horse Radish Peroxidase

Ig

immunoglobin
40

IGV

Integrated Genomics Viewer

IT

Intratumoral injection

IV

Intravenous injection

LC3

Light Chain 3

MOI

Multiplicity of Infection

OD

Opitical Density or absorbance

PBS

Phosphate Buffered Saline

PFU

Plaque Forming Units

PI

Protease Inhibitor

RCF

Relative Centrifugal Force

RIPA

Radioimmunoprecipitation Assay Buffer

RPM

Revolutions Per Minute

RPMI

Roswell Park Memorial Institute

SC

Subcutaneous injection

SDS

Sodium Dodecyl Sulfate

SEER

Surveillance Epidemiology and End Results

TBST

Tris-Buffered saline with Tween 20

TNM

Tumor Nodes Metastatsis

Wt

Wildtype
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